Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd > Anybody Notice Date Modified Changed Yesterday?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(7)
•••
Comment by Valuehunter72on Jun 18, 2020 4:39pm
99 Views
Post# 31166714

RE:RE:Anybody Notice Date Modified Changed Yesterday?

RE:RE:Anybody Notice Date Modified Changed Yesterday?

Not sure at this point 359.

comparing my screenshots, I do not see the change.  Not sure what modified on their end means yet.

Still waiting for David to crawl out of his hole and update investors what is going on with funding through the Strategic Innovation Fund.
 

This part in particular...  

  • Seeking funding from the Strategic Innovation Fund to support COVID-19 vaccine and therapy clinical trials
And...when I click on the highlighted YES, this part..

Funding Expected in Current Financial Year

and it says YES

Whats that all about David?

Lester.....c mon.....you know about this....


 
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities